3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase 3
1
Phase 2
1
Status
Completed
48
Terminated
19
Unknown
11
Recruiting
4
Active not recruiting
4
Sponsor Class
OTHER
2
INDUSTRY
2
Study Type
Interventional
4
Sponsor
Cancer Type
Tumor-Agnostic
3
CNS
1
Conditions
Breast Neoplasms
47
Rectal Neoplasms
29
Stomach Neoplasms
24
Colorectal Neoplasms
24
Triple Negative Breast Neoplasms
18
Neoplasm Metastasis
10
Colonic Neoplasms
10
Nasopharyngeal Carcinoma
9
Locally Advanced Rectal Cancer
7
Esophageal Neoplasms
7
Biliary Tract Neoplasms
7
Pancreatic Neoplasms
5
Brain Neoplasms
5
Adenocarcinoma Of Esophagus
5
Adenocarcinoma
5
Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Neuroendocrine Tumors
3
HER2-positive Breast Cancer
3
Gastrointestinal Neoplasms
3
Cholangiocarcinoma
3
Advanced Solid Tumors
3
Recurrence
2
Neoplasm, Residual
2
Meningeal Neoplasms
2
Locally Advanced Colorectal Cancer
2
Esophageal Squamous Cell Carcinoma
2
Early Low Rectal Cancer
2
Colorectal Cancer Metastatic
2
Interventions
pembrolizumab
38
Blood Specimen Collection
38
Bevacizumab
22
Surveys and Questionnaires
18
Standard of Care
18
Radiotherapy
17
Exercise
17
Carboplatin
17
Nivolumab
15
atezolizumab
14
Paclitaxel
14
Cisplatin
14
Drug Therapy
13
Fluorouracil
12
Cyclophosphamide
12
Cetuximab
11
Trastuzumab
10
Pemetrexed
10
Leucovorin
10
Docetaxel
10
Dexamethasone
10
Oxaliplatin
9
Biopsy
9
pertuzumab
8
olaparib
8
Temozolomide
8
Panitumumab
8
Observation
8
Irinotecan
8
abemaciclib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasms
×
Capecitabine
×
Clear all
NCT03899155
2026-05-27
Pan Tumor Rollover Study
Bristol-Myers Squibb
Phase 2
Recruiting
1,500 enrolled
NCT06901531
2026-04-29
LUCERNA
Astellas Pharma Inc
Phase 3
Recruiting
500 enrolled
NCT04333706
2026-03-10
EMPOWER
University of Southern California
Phase 1/2
Recruiting
65 enrolled
NCT03213002
2025-04-09
CAPTEM
Northwell Health
Phase 1/2
Recruiting
67 enrolled